Pfizer's Bosulif set for EU approval in CML
11:05 EST 18 Jan 2013 | SCRIP
The EU's CHMP has recommended that Pfizer's oral Bcr-Abl kinase inhibitor bosutinib (Bosulif 100mg and 500mg) be granted conditional marketing authorisation for the treatment of chronic myelogenous leukaemia (CML). It will be specifically.....
Original Article: Pfizer's Bosulif set for EU approval in CML
More From BioPortfolio on "Pfizer's Bosulif set for EU approval in CML"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
